| answer text |
<p>The National Institute for Health and Care Excellence (NICE) is the independent
body that provides guidance on the prevention and treatment of ill health and the
promotion of good health and social care. Through its technology appraisal programme,
NICE makes recommendations for the National Health Service on whether selected drugs
and other treatments represent an effective use of NHS resources. NHS commissioners
are legally required to fund drugs and treatments recommended through NICE’s technology
appraisal programme.</p><p> </p><p>NICE is currently developing technology appraisal
guidance on two drugs for the prevention of migraines; erenumab and fremanuzumab.
The expected date of NICE’s final guidance is currently to be confirmed. In the absence
of positive guidance from NICE, it is for commissioners to make decisions on whether
to fund this treatment based on an assessment of the available evidence.</p><p> </p><p>
</p><p><strong> </strong></p><p><strong> </strong></p>
|
 |
